Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/AstraZeneca Come Together Over Statin/Fibrate Combo

This article was originally published in The Pink Sheet Daily

Executive Summary

Two parallel programs have been initiated in search of the next combination cholesterol management drug.

You may also be interested in...



Abbott, AstraZeneca To Combine Next-Generation Fenofibrate With Crestor In Phase III

The companies are aiming to submit the lipid-regulating combination in 2009.

Abbott, AstraZeneca To Combine Next-Generation Fenofibrate With Crestor In Phase III

The companies are aiming to submit the lipid-regulating combination in 2009.

Sciele/LifeCycle’s “Meltdose” Fenofibrate Clears FDA

Sciele will launch fenofibrate formulation in 40 mg and 120 mg strengths for hyperlipidemia and hypertriglyceridemia by the end of 2007.

Related Content

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel